Mark Womack

Recent Posts by Mark Womack:

AGC Biologics to Expand Biopharmaceutical CDMO Capacity


Doubling the production capacity at its site in Denmark to address strong demand


(SEATTLE), November 30, 2020 -- AGC Biologics announced that it will increase the production capacity of its Copenhagen facility. AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space. The total investment for this expansion is estimated to be approximately €160M, and the start of operation is scheduled for 2023.

AGC Biologics and Horizon Therapeutics plc Expand Partnership


Horizon’s TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics’ new facility in Boulder, CO


(SEATTLE), October 29, 2020 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therapeutics plc (Nasdaq: HZNP) is expanding to produce Horizon’s Thyroid Eye Disease (TED) treatment, TEPEZZA, at AGC’s new facility in Boulder, CO. The state-of-the-art facility includes two 20,000L stainless steel mammalian bioreactors which AGC is offering to customers who need very high-volume commercial production.

Follow Us
Join us on LinkedIn Follow us on Twitter